Understanding the Bavarian Nordic Stock Symbol: A Comprehensive Guide

Bavarian Nordic's stock symbol is listed on the Nasdaq Copenhagen stock exchange, specifically under the ticker code "BVN".

The company's stock is also listed on the OTCQX market in the United States, under the ticker code "BVNRY".

Bavarian Nordic is a Danish biotechnology company specializing in the development and production of vaccines and pharmaceuticals.

Its stock symbol has been widely recognized and traded on various international markets, giving investors a platform to participate in the company's growth and success.

On a similar theme: Stock Symbol B

The Bavarian Nordic stock symbol is listed on the NASDAQ Copenhagen stock exchange under the ticker symbol BAVA.

Bavarian Nordic's financial performance has been stable, with a revenue growth of 15% in 2020 compared to the previous year.

The company has a strong cash position, with a cash and cash equivalents balance of DKK 1.4 billion as of December 2020, which provides a solid foundation for future growth.

Bavarian Nordic's financial statements are available on their website, providing investors with a detailed overview of the company's financial performance.

Take a look at this: Cash App Ticker Symbol

Financial Strength is a crucial aspect of any company's overall health. A company with strong financials is better equipped to weather financial storms and make strategic decisions.

The Quick Ratio is a key indicator of a company's liquidity, and a ratio of 0.95, as seen in BAVA, suggests that the company may be struggling to meet its short-term obligations. In contrast, a Quick Ratio of 7.16, as seen in GUBRA, indicates a strong ability to meet short-term obligations.

The Current Ratio provides further insight into a company's liquidity, with BAVA's ratio of 1.69 suggesting a moderate ability to meet short-term obligations. GUBRA's Current Ratio of 7.24 is significantly higher, indicating a strong ability to meet short-term obligations.

Interest Coverage is another important metric, with BAVA's ratio of 12.93 indicating a strong ability to meet interest payments. In contrast, GUBRA's ratio of -11.85 suggests that the company may be struggling to meet interest payments, and 300149's ratio of -32.18 is even more concerning.

Here's a summary of the financial strength of these three companies:

Bavarian Nordic has reported its results for the first nine months of the year.

The company anticipates a boost in biodefense funding from the incoming U.S. administration.

This is despite concerns that the nomination of Robert F. Kennedy Jr. as health secretary could have a negative impact on the company's prospects.

Bavarian Nordic has reaffirmed its upgraded guidance for FY24, which suggests a positive outlook for the company's future financial performance.

The "Select Symbol" section is a crucial part of accessing financial information. This section lists various stock exchanges and their corresponding symbols.

You can find the following stock exchanges listed in this section: Denmark, Germany, United States, United Kingdom, Austria, and Switzerland.

Here are some specific symbols mentioned in the section:

These symbols can be used to access specific financial information about the companies listed on these exchanges.

Bavarian Nordic initiated a share buy-back program of up to DKK 150 million in the first quarter of 2025.

The program was announced on December 11, 2024, and was intended to be launched in the first quarter of 2025.

Bavarian Nordic A/S (OMX: BAVA) initiated a share buy-back program of up to DKK 150 million on January 9, 2025.

The share buy-back program was completed on January 31, 2025, after reaching its target of DKK 150 million.

Transactions under the share buy-back program were announced on January 27, 2025, and January 20, 2025, with the company repurchasing shares under the program.

Bavarian Nordic A/S (OMX: BAVA) announced its intent to launch a share buy-back program of up to DKK 150 million on December 11, 2024.

Bavarian Nordic's stock symbol is listed on the NASDAQ Copenhagen stock exchange under the ticker code "BAVA".

The company's strong financial performance has been a key driver of investor interest, with revenues growing from $134 million in 2015 to $444 million in 2020.

Bavarian Nordic's pipeline of vaccine candidates has also generated significant interest among investors, with several promising candidates in various stages of development.

The company's expertise in vaccine development has been a major factor in its success, with a proven track record of developing and commercializing vaccines for infectious diseases.

Bavarian Nordic's mpox vaccine sales have declined post-outbreak, causing reduced revenue and highlighting its reliance on outbreak-driven demand.

The company's reliance on outbreak-driven demand is a concern, as it can lead to fluctuations in revenue.

Bavarian Nordic's Travel Health segment has demonstrated strength, however, with a diversified portfolio that's less dependent on mpox vaccine sales.

This diversification is a positive sign, as it can help stabilize revenue and reduce the company's reliance on a single product.

The Travel Health segment is a key area of focus for Bavarian Nordic, offering a range of products that can help mitigate the impact of declining mpox vaccine sales.

By diversifying its portfolio, Bavarian Nordic is better positioned to navigate the challenges of a post-outbreak market.

A unique perspective: Cardinal Health Ticker Symbol

Nykredit recently raised their target price for Bavarian Nordic A/S to DKK 260, reiterating a Buy recommendation.

Danske Bank lowered their target price for Bavarian Nordic to DKK 370, still maintaining a Buy recommendation.

Kempen also lowered their target price, this time to DKK 300, while reaffirming their Buy recommendation.

Nordea took a more cautious approach, lowering their recommendation from Buy to Hold.

Carnegie Group, on the other hand, upgraded their recommendation for Bavarian Nordic to Buy, also lifting their target price.

Broaden your view: History of Stock Price Symbol Svm

The current market situation for the Bavarian Nordic stock symbol is a good place to start. The open price for the stock is 173.25.

The stock's high price for the day is 178.25, which is a significant increase from its low price of 173.25. The bid price is 174.15, and the offer price is 174.35.

The stock's previous close was 172.55, and it's worth noting that the previous close was lower than the current open price. The average volume for the stock is 384.85k, which is a relatively high number.

The shares outstanding for the stock are 78.85m, and the free float is 77.34m. The P/E (TTM) for the stock is 12.02, which is a relatively low ratio. The market cap for the stock is 13.61bn DKK.

Here's a summary of the key statistics: